Loading the player...
Cemiplimab NSCLC Clinical Trial Halts Due to “Highly Significant” OS Improvement
A Phase 3 trial of cemiplimab as a first line monotherapy for patients with advanced NSCLC has halted early due to “highly significant improvement in overall survival,” according to the manufacturer.
Cemiplimab is an anti-PD-1 inhibitor immunotherapy currently approved for treatment of cutaneous squamous cell carcinoma.
The Phase 3 trial included 712 with locally advanced, PD-L1 positive, NSCLC.
Patients were randomized 1:1 to receive 350mg of cemiplimab every 3 weeks or standard chemotherapy care for four to six cycles.
Results showed that cemiplimab “decreased the risk of death by 32.4%.” The independent Data Monitoring Committee recommended that the clinical trial halt early due to these results.
According to the manufacturer, these data will be used to support a regulatory submission in 2020.
Cemiplimab is an anti-PD-1 inhibitor immunotherapy currently approved for treatment of cutaneous squamous cell carcinoma.
The Phase 3 trial included 712 with locally advanced, PD-L1 positive, NSCLC.
Patients were randomized 1:1 to receive 350mg of cemiplimab every 3 weeks or standard chemotherapy care for four to six cycles.
Results showed that cemiplimab “decreased the risk of death by 32.4%.” The independent Data Monitoring Committee recommended that the clinical trial halt early due to these results.
According to the manufacturer, these data will be used to support a regulatory submission in 2020.